The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
Abstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunothe...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-09-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-98131-4 |
| _version_ | 1797752717377011712 |
|---|---|
| author | Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun |
| author_facet | Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun |
| author_sort | Kai Li |
| collection | DOAJ |
| description | Abstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness. |
| first_indexed | 2024-03-12T17:08:33Z |
| format | Article |
| id | doaj.art-bbf27ca926fd41d7b6bf1a3437ce9d68 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-12T17:08:33Z |
| publishDate | 2021-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-bbf27ca926fd41d7b6bf1a3437ce9d682023-08-06T11:15:36ZengNature PortfolioScientific Reports2045-23222021-09-0111111210.1038/s41598-021-98131-4The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomasKai Li0Lei Ma1Ye Sun2Xiang Li3Hong Ren4Shou-Ching Tang5Xin Sun6Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Anesthesiology and Perioperative Medicine, Operating Centre, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Anesthesiology and Operation, Operating Centre, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityUniversity of Mississippi Medical Center, Cancer Center and Research Institute, University of MississippiDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong UniversityAbstract Immune checkpoint blockade, an immunotherapy, has been applied in multiple systemic malignancies and has improved overall survival to a relatively great extent; whether it can be applied in breast cancer remains unknown. We endeavored to explore possible factors that may influence immunotherapy outcomes in breast cancer using several public databases. The possible treatment target TNF superfamily member 4 (TNFSF4) was selected from many candidates based on its abnormal expression profile, survival-associated status, and ability to predict immune system reactions. For the first time, we identified the oncogenic features of TNFSF4 in breast carcinoma. TNFSF4 was revealed to be closely related to treatment that induced antitumor immunity and to interact with multiple immune effector molecules and T cell signatures, which was independent of endocrine status and has not been reported previously. Moreover, the potential immunotherapeutic approach of TNFSF4 blockade showed underlying effects on stem cell expansion, which more strongly and specifically demonstrated the potential effects of applying TNFSF4 blockade-based immunotherapies in breast carcinomas. We identified potential targets that may contribute to breast cancer therapies through clinical analysis and real-world review and provided one potential but crucial tool for treating breast carcinoma that showed effects across subtypes and long-term effectiveness.https://doi.org/10.1038/s41598-021-98131-4 |
| spellingShingle | Kai Li Lei Ma Ye Sun Xiang Li Hong Ren Shou-Ching Tang Xin Sun The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas Scientific Reports |
| title | The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas |
| title_full | The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas |
| title_fullStr | The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas |
| title_full_unstemmed | The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas |
| title_short | The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas |
| title_sort | immunotherapy candidate tnfsf4 may help the induction of a promising immunological response in breast carcinomas |
| url | https://doi.org/10.1038/s41598-021-98131-4 |
| work_keys_str_mv | AT kaili theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT leima theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT yesun theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xiangli theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT hongren theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT shouchingtang theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xinsun theimmunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT kaili immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT leima immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT yesun immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xiangli immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT hongren immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT shouchingtang immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas AT xinsun immunotherapycandidatetnfsf4mayhelptheinductionofapromisingimmunologicalresponseinbreastcarcinomas |